Cytosorbents Corp. buy Quitte
Start price
11.01.16
/
50%
€4.45
Target price
11.07.16
€5.14
Performance (%)
-1.62%
End price
11.07.16
€4.37
Summary
This prediction ended on 11.07.16 with a price of €4.37. With a performance of -1.62%, the BUY prediction by Quitte finished with a loss. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Cytosorbents Corp. | -2.727% | -2.727% | -45.519% | -76.116% |
| iShares Core DAX® | 0,99 % | 8,31 % | 7,03 % | 49,79 % |
| iShares Nasdaq 100 | 2,07 % | 16,77 % | 35,95 % | 96,63 % |
| iShares Nikkei 225® | 2,27 % | 15,61 % | 46,57 % | 69,05 % |
| iShares S&P 500 | 1,04 % | 11,08 % | 26,46 % | 68,09 % |
Comments by Quitte for this prediction
In the thread Cytosorbents Corp. diskutieren
auf Wachstumskurs
Growth Trajectory Continues with Record CytoSorb® Sales of Approximately $1.5M in Q4 2015 and Approximately $4.0M in 2015
MONMOUTH JUNCTION, N.J., Jan. 11, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients worldwide, issues a letter to its stockholders from Chief Executive Officer, Dr. Phillip Chan.
(Laufzeit überschritten)
Stopped prediction by Quitte for Cytosorbents Corp.
Cytosorbents Corp.
Start price
Target price
Perf. (%)
€9.12
06.11.18
06.11.18
€16.24
06.05.19
06.05.19
-24.33%
06.05.19
06.05.19
Cytosorbents Corp.
Start price
Target price
Perf. (%)
€5.14
22.12.16
22.12.16
€6.48
22.06.17
22.06.17
-23.68%
22.06.17
22.06.17